Edoxaban TsOH salt - CAS 480449-71-6
Catalog number: 480449-71-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Factor Xa
Edoxaban is an oral factor Xa (FXa) inhibitor, also contraindicated in patients with active pathological bleeding.
White to Off-White Solid
Edoxaban Tosylate; N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;4-methylbenzenesulfonic acid;
Soluble in DMSO
Store at -20 °C
A direct factor Xa inhibitor.
Quality Standard:
Enterprise Standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Canonical SMILES:
Current Developer:
Daiichi Sankyo Company
1.Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
Turpie AG Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1238-47. Epub 2007 Mar 22.
Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing anticoagulants are effective, their use is limited by parenteral administration or the requirement for frequent monitoring and subsequent dose adjustment. Therefore, there is an urgent need for novel, oral agents with a predictable anticoagulant action. Because of its key position in the coagulation cascade and its limited roles outside of coagulation, Factor Xa has emerged as an attractive target for novel anticoagulants. As a result, the past decade has witnessed an explosion of research into small-molecule, oral, direct Factor Xa inhibitors, and several are now in clinical development. Rivaroxaban, LY517717, YM150, apixaban, PRT054021, and DU-176b, among others, have shown considerable promise; rivaroxaban is currently furthest ahead in its developmental program, having entered phase III in 3 indications. It is hoped that, before long, these anticoagulants will allow us to enter an era of convenient, oral anticoagulation, without the need for regular monitoring or dose adjustment.
2.Gateways to clinical trials.
Tomillero A;Moral MA Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46.
ABT-869, Acadesine, Acetylsalicylic acid/omeprazole, Adefovir, Adefovir dipivoxil, AEG-35156, Agatolimod sodium, Albiglutide, Alemtuzumab, Alipogene tiparvovec, Alogliptin benzoate, AMG-386, Amrubicin hydrochloride, Apremilast, Aripiprazole, Asoprisnil, Atorvastatin/fenofibrate, AVN-944, Axitinib; Belinostat, Bevacizumab, BHT-3021, BI-2536, Biapenem, Bilastine, Biphasic insulin aspart, Blinatumomab, Bortezomib, Bosentan; Catumaxomab, CD-NP, Cediranib, Certolizumab pegol, Cetuximab, Choline fenofibrate, Ciclesonide, CK-1827452,Clevudine, Clofarabine, CSL-360, CYT-997; Dapagliflozin, Darinaparsin, Denosumab, Densiron 68, Desloratadine, Dulanermin; Edoxaban tosilate, Emtricitabine, Entecavir, Erlotinib hydrochloride, Everolimus, Exenatide, Ezetimibe, Ezetimibe/simvastatin; Fidaxomicintiacumiv, Fulvestrant; G-207, GCR-8015, Gefitinib, Ghrelin (human), Glufosfamide; HPV16L1E7CVLP; Ibutamoren mesilate, Imatinib mesylate, Insulin detemir, Insulin glargine, Iodine (I131) tositumomab, Istaroxime, ITMN-191, Ixabepilone; JZP-4, Lenalidomide; Levetiracetam, Linaclotide acetate, Liposomal cytarabine/daunorubicin, Liposomal doxorubicin, Liraglutide, LY-518674; Milatuzumab, MMR-V, Motesanib diphosphate, Mycophenolic acid sodium salt; Niacin/simvastatin; Obatoclax mesylate, Odanacatib; Paclitaxel nanoparticles, Paclitaxel-eluting stent, Pazufloxacin, PBT-2, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/ribavirin, Pemetrexed disodium, Perampanel, PfCP2.
3.Long-term benefits of preventing venous thromboembolic events.
Cohen AT Curr Med Res Opin. 2012 Jun;28(6):877-89. doi: 10.1185/03007995.2012.688737. Epub 2012 May 24.
BACKGROUND: ;Venous thromboembolism (VTE) and its long-term secondary complications are major health problems associated with high rates of morbidity and mortality and considerable costs for healthcare systems. Many patients receive suboptimal therapy, despite the availability of established and effective agents (including low molecular weight heparins, unfractionated heparin, fondaparinux and vitamin K antagonists) and evidence-based, internationally recognised guidelines. Limited knowledge of guidelines, concerns about bleeding risks and the inconvenience of parenteral administration and routine coagulation monitoring contribute to non-adherence to guidelines. Newer oral anticoagulants such as rivaroxaban, dabigatran etexilate, apixaban and edoxaban, which do not have the limitations of established anticoagulants, have been developed.;METHOD: ;Phase III randomised controlled trials for the treatment of acute VTE or for secondary prevention of recurrent VTE were identified in the PubMed and ClinicalTrials.gov databases. The search was limited to phase III studies and performed up to 26 March 2012 with the terms 'rivaroxaban OR Xarelto', 'dabigatran OR Pradaxa', 'apixaban OR Eliquis' and 'edoxaban OR DU-176b OR Lixiana'.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Factor Xa Products

CAS 536748-46-6 Eribaxaban

(CAS: 536748-46-6)

Eribaxaban is an orally active inhibitor of coagulation factor Xa (activated factor X). It has anticoagulant activity and is used as an anticoagulant drug. It i...

CAS 366789-02-8 Rivaroxaban

(CAS: 366789-02-8)

Rivaroxaban (Xarelto; BAY 59-7939) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembol...

CAS 503612-47-3 Apixaban

(CAS: 503612-47-3)

Apixaban (INN, trade name Eliquis) is an anticoagulant for the prevention of venous thromboembolism and the prevention of stroke in atrial fibrillation. It is a...

CAS 56974-61-9 Gabexate mesylate

Gabexate mesylate
(CAS: 56974-61-9)

Gabexate is a serine protease inhibitor that inhibits trypsin (IC50= 9.4μM), plasmin (IC50= 30μM), plasma kallikrein (IC50= 41μM) and thrombin (IC50= 110μM). It...

CAS 193153-04-7 Otamixaban

(CAS: 193153-04-7)

Otamixaban, is a novel, selective, rapid acting, competitive, reversible and direct fXa inhibitor of the β-aminoester class. It was in Phase-III clinical develo...

CAS 330942-05-7 betrixaban

(CAS: 330942-05-7)

Betrixaban is a long-acting anticoagulant used for the treatment of venous thromboembolism (VTE) caused by limited mobility or some other factors in adult patie...

CAS 280118-23-2 BMS-740808

(CAS: 280118-23-2)

BMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa with Ki of 0.03 nM.

CAS 480449-71-6 Edoxaban TsOH salt

Edoxaban TsOH salt
(CAS: 480449-71-6)

Edoxaban is an oral factor Xa (FXa) inhibitor, also contraindicated in patients with active pathological bleeding.

CAS 130952-46-4 Ozagrel sodium

Ozagrel sodium
(CAS: 130952-46-4)

The sodium salt form of Ozagrel which has been studied to influence monophenolase and diphenolase activities and also restrain the synthesis of thromboxane A2 s...

CAS 480449-70-5 Edoxaban

(CAS: 480449-70-5)

Edoxaban is an oral factor Xa (FXa) inhibitor, also contraindicated in patients with active pathological bleeding.

CAS 114870-03-0 Fondaparinux sodium

Fondaparinux sodium
(CAS: 114870-03-0)

Fondaparinux sodium is a factor Xa inhibitor that mediates the interaction of herparin with antithrombins. It is used for the prevention of venous thromboemboli...

CAS 1229194-11-9 Edoxaban tosylate monohydrate

Edoxaban tosylate monohydrate
(CAS: 1229194-11-9)

In human plasma, Edoxaban doubles prothrombin time and activates partial thromboplastin time at 0.256 and 0.508 μM, respectively

CAS 288079-93-6 BMS-344577

(CAS: 288079-93-6)

BMS-344577 is aroylguanidine-based lactam derivative, which is a potent FXa inhibitor (FXa IC(50)=4 nM, EC(2xPT)=7 microM).

Chemical Structure

CAS 480449-71-6 Edoxaban TsOH salt

Quick Inquiry

Verification code

Featured Items